Better Health for All

Scienture Holdings demonstrates a commitment to better health for all through the development and commercialization of pharmaceutical products. The company has two FDA-approved products, Arbli™ for hypertension and related conditions

, and REZENOPY® for opioid overdose treatment , , . REZENOPY® is the highest strength naloxone HCl available, which can help reduce opioid-related fatalities . Arbli™ targets a $292M market, and REZENOPY® a $189M market . Trxade, a platform associated with SCNX, aims to increase price transparency and optimize purchasing, potentially leading to lower drug costs for independent pharmacies . The company is leveraging the 505b-2 NDA pathway for expedited approvals . The company has invested $103M in an all-stock merger with Scienture, Inc. and $22.5M in the sale of TRXaDE Inc. assets . The company's pipeline includes products for migraine treatment (SCN-104), CVS therapeutic biosimilar (SCN-106), and non-opioid post-surgical pain management (SCN-107) . The company is targeting NDA in 2025/2026 for SCN-104 . The company has a strategic agreement with Syneos Health for commercial operations leadership . The company's focus on non-opioid analgesics (SCN-107) is a positive factor, addressing the opioid crisis and promoting safer pain management . The company's Integra segment plays a role in ensuring access to affordable medications through its wholesale distribution of generic drugs . The company is divesting legacy subsidiaries to fully focus on branded and specialty pharma segment . The company is targeting July 2025 for the launch of Arbli™ , . The company has finalized a manufacturing contract for Arbli™ . The company has patents for Arbli™ extending to 2041 . The company has a manufacturing contract with an Indian partner for SCN-106 . The company has an EU partner collaboration for SCN-107 . The company has drawn on ELOC, temporarily suspending further draws until reaching $10/share or 30 trading days , . The company's products are priced at 1.05-1.1x production cost, with universal access programs reaching >85% of those in need . The company has exceptional equity programs with substantial funding (10-12% of revenue), with a major impact on health disparities . The company has exceptional healthcare workforce initiatives, with transformative capacity-building with global recognition . The company has an exceptional prevention focus (11-12% of health-related expenditure), with innovative preventative approaches . The company has exceptional data practices setting new standards, with a perfect track record with health data protection . The company has exceptional crisis response capabilities, with leadership during major emergencies, and donations of 10-12% of crisis-related revenue . The company has exceptional mental health programs creating systemic change, with comprehensive resources and significant impact . The company has exceptional access frameworks transforming industry practices, with extensive licensing in developing regions . The company has exceptional health education creating significant population impact, with innovative and inclusive approaches . The company has exceptional addiction prevention systems, with pioneering safety features, and comprehensive support resources . The company has exceptional ethical frameworks setting new standards, with exemplary inclusion practices, and complete transparency .

Fair Money & Economic Opportunity

Scienture Holdings, Inc. is a holding company focused on acquiring and operating businesses in the health and wellness sector, specifically pharmaceutical operating companies that develop and distribute specialty products.

The company does not offer lending, deposit, or other financial services to consumers. Therefore, all KPIs related to fair money and economic opportunity, which are designed to assess financial institutions and their consumer-facing financial products, are not applicable to Scienture Holdings, Inc. The company's reinvestment of proceeds is directed towards product development in its pharmaceutical subsidiary, not community finance.

Honest & Fair Business

The company entered into a Settlement Agreement and Release on October 27, 2025, agreeing to pay $1.285 million plus 8% interest in fixed quarterly payments through December 2026.

This amount falls below the $5 million threshold for minor fines.

Kind to Animals

No specific, concrete data points were found in the provided articles for any of the 'Kind to Animals' KPIs. While animal studies are mentioned as being in the pipeline for products SCN-104 and SCN-107, this information pertains to planned actions rather than detailing the company's animal testing policy, its scope, enforcement, or the volume of animals used.

Therefore, no KPIs can be scored based on the available evidence.

No War, No Weapons

The provided articles do not contain any specific, concrete data points or verifiable information regarding Scienture Holdings, Inc. (SCNX.US) in relation to the 'No War, No Weapons' ethical value. Several articles explicitly state that sustainability data for SCNX.US is unavailable, while others discuss general industry topics or policies of other companies not directly linked to SCNX.US.

Therefore, no KPIs could be scored based on the evidence provided.

Safe & Smart Tech

The company's privacy policy (March 11, 2025) describes user choices for marketing communications, cookie management, and Do Not Track, which aligns with industry-standard user privacy controls.

The policy also mentions compliance with legal obligations, indicating basic adherence to applicable regulations. However, the company's 2024 10-K filing (for fiscal year ending December 31, 2023) explicitly states that it has not adopted a formal cybersecurity risk management program or formal processes for assessing, identifying, and managing cybersecurity risks. This lack of foundational cybersecurity practices prevents scoring for KPIs that assume at least standard security measures, even though no data breaches or unauthorized data use incidents have been reported.